These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

130 related articles for article (PubMed ID: 17322962)

  • 1. Administration of infliximab in general practitioners' offices is safe.
    Stuby U; Biesenbach G; Pieringer H
    Clin Rheumatol; 2007 Nov; 26(11):1863-6. PubMed ID: 17322962
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Evaluation of the safety and satisfaction of rheumatic patients with accelerated infliximab infusion.
    de Carvalho JF; Dos Santos MNP; de Oliveira JMV; Lanty Silva ANS; de Araujo RPC; Cardozo JB
    Adv Rheumatol; 2018 Aug; 58(1):22. PubMed ID: 30657070
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Continuation of treatment with infliximab in ankylosing spondylitis: 2-yr open follow-up.
    Gossec L; Le Henanff A; Breban M; Vignon E; Claudepierre P; Devauchelle V; Wendling D; Lespessailles E; Euller-Ziegler L; Sibilia J; Perdriger A; Alexandre C; Dougados M
    Rheumatology (Oxford); 2006 Jul; 45(7):859-62. PubMed ID: 16436489
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Open label study to assess infliximab safety and timing of onset of clinical benefit among patients with rheumatoid arthritis.
    Shergy WJ; Isern RA; Cooley DA; Harshbarger JL; Huffstutter JE; Hughes GM; Spencer-Smith EA; Goldman AL; Roth SH; Toder JS; Warner D; Quinn A; Keenan GF; Schaible TF;
    J Rheumatol; 2002 Apr; 29(4):667-77. PubMed ID: 11950005
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Assessment of effectiveness and safety of biosimilar infliximab (CT-P13) in a real-life setting for treatment of patients with active rheumatoid arthritis or ankylosing spondylitis.
    Codreanu C; Šírová K; Jarošová K; Batalov A
    Curr Med Res Opin; 2018 Oct; 34(10):1763-1769. PubMed ID: 29439591
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Erythema nodosum associated with infliximab therapy.
    Rosen T; Martinelli P
    Dermatol Online J; 2008 Apr; 14(4):3. PubMed ID: 18627725
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Accelerated infliximab infusions are safe and well tolerated in patients with inflammatory bowel disease.
    Clare DF; Alexander FC; Mike S; Dan G; Allan F; Lisa W; Peter HJ
    Eur J Gastroenterol Hepatol; 2009 Jan; 21(1):71-5. PubMed ID: 19060632
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Safety and cost of infliximab for the treatment of Belgian pediatric patients with Crohn's disease.
    De Greef E; Hoffman I; D'Haens G; Van Biervliet S; Smets F; Scaillon M; Dewit O; Peeters H; Paquot I; Alliet P; Arts W; Hauser B; Vermeire S; Van Gossum A; Rahier JF; Etienne I; Louis E; Coche JC; Mahachie John J; Van Steen K; Veereman G; ;
    Acta Gastroenterol Belg; 2012 Dec; 75(4):425-31. PubMed ID: 23402086
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Infusion reactions to infliximab in children and adolescents: frequency, outcome and a predictive model.
    Crandall WV; Mackner LM
    Aliment Pharmacol Ther; 2003 Jan; 17(1):75-84. PubMed ID: 12492735
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Clinical pharmacokinetics and use of infliximab.
    Klotz U; Teml A; Schwab M
    Clin Pharmacokinet; 2007; 46(8):645-60. PubMed ID: 17655372
    [TBL] [Abstract][Full Text] [Related]  

  • 11. [Adverse events during biological therapy -- focusing on dermatological side-effects].
    Nagy G; Lukács K; Sziray A; Fazekas K; Florián A; Tamási L; Károlyi Z
    Orv Hetil; 2011 Feb; 152(6):212-20. PubMed ID: 21278026
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Infliximab heals intestinal inflammatory lesions and restores growth in children with Crohn's disease.
    Borrelli O; Bascietto C; Viola F; Bueno de Mesquita M; Barbato M; Mancini V; Bosco S; Cucchiara S
    Dig Liver Dis; 2004 May; 36(5):342-7. PubMed ID: 15191204
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Review and expert opinion on prevention and treatment of infliximab-related infusion reactions.
    Lecluse LL; Piskin G; Mekkes JR; Bos JD; de Rie MA
    Br J Dermatol; 2008 Sep; 159(3):527-36. PubMed ID: 18627374
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Annual acquisition and administration cost of biologic response modifiers per patient with rheumatoid arthritis, psoriasis, psoriatic arthritis, or ankylosing spondylitis.
    Bonafede M; Joseph GJ; Princic N; Harrison DJ
    J Med Econ; 2013 Sep; 16(9):1120-8. PubMed ID: 23808901
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Efficacy and safety of reducing duration of infliximab infusion.
    Fukuyo S; Saito K; Yamaoka K; Sawamukai N; Hirata S; Nawata M; Iwata S; Tanaka Y
    Mod Rheumatol; 2014 Mar; 24(2):275-80. PubMed ID: 24251990
    [TBL] [Abstract][Full Text] [Related]  

  • 16. [Suspected cases of severe side effects after infliximab (Remicade) in Germany].
    Andus T; Stange EF; Höffler D; Keller-Stanislawski B
    Med Klin (Munich); 2003 Aug; 98(8):429-36. PubMed ID: 12928808
    [TBL] [Abstract][Full Text] [Related]  

  • 17. The safety of infliximab infusions in the community setting.
    Ducharme J; Pelletier C; Zacharias R
    Can J Gastroenterol; 2010 May; 24(5):307-11. PubMed ID: 20485705
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Successful induction of tolerance to infliximab in patients with Crohn's disease and prior severe infusion reactions.
    Duburque C; Lelong J; Iacob R; Seddik M; Desreumaux P; Fournier C; Wallaert B; Cortot A; Colombel JF
    Aliment Pharmacol Ther; 2006 Sep; 24(5):851-8. PubMed ID: 16918890
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Golimumab: Review of the efficacy and tolerability of a recently approved tumor necrosis factor-α inhibitor.
    Boyce EG; Halilovic J; Stan-Ugbene O
    Clin Ther; 2010 Sep; 32(10):1681-703. PubMed ID: 21194591
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Acute and long-term effect of infliximab on humoral and echocardiographic parameters in patients with chronic inflammatory diseases.
    Tomáš L; Lazúrová I; Pundová L; Oetterová M; Zakuciová M; Petrášová D; Studenčan M
    Clin Rheumatol; 2013 Jan; 32(1):61-6. PubMed ID: 23010850
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 7.